Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10172936-B2
Publication Date
2019-01-08
Expiration Date
Abstract
A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell.
Core Innovation
The invention relates to peptide/polymer particle vaccine formulations that comprise a pharmaceutically acceptable carrier and a plurality of groups of substantially spherical biocompatible polymer particles. Each group includes an antigen embedded in the polymer, and the antigen in each group consists only of a single species comprising eight to twenty amino acids, with the antigen species different across different particle groups.
The particle diameter is selected so that only a single particle can be consumed by an antigen presenting cell. The antigen presenting cells referenced include dendritic cells and macrophages, and the particle diameter constraint is described in terms of reducing immunodominance and controlling epitope presentation by limiting particle consumption per antigen presentation event.
The document also describes vaccine formulations where three particle groups each embed a distinct single antigen species, as well as embodiments with additional groups of particles embedding additional antigens that are different from antigens in other groups. The biocompatible polymer is exemplified by PLGA, polycaprolactone, polyglycolide, polylactic acid, and poly-3-hydroxybutyrate, and the formulations can include optional adjuvants including monophosphoryl lipid A in the pharmaceutically acceptable carrier.
Claims Coverage
The independent claims are directed to compositions and vaccine compositions with three groups of polymer-embedded antigen particles, each group containing only a single antigen species of eight to twenty amino acids, and a particle diameter constraint sized so only one particle can be consumed by an antigen presenting cell. Across the independent claims, the core inventive features are the multi-group, single-species-per-group antigen embedding and the single-particle-consumption particle sizing constraint.
Three-group polymer-embedded single-species antigen particles with single-particle consumption sizing
A composition comprising a pharmaceutically acceptable carrier; a first group of substantially spherical biocompatible-polymer particles with a first antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer; a second group with a second antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the second antigen different from the first; and a third group with a third antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the third antigen different from both the first and second; wherein each particle has a diameter from 10 microns×120% to 25 microns×120% such that only a single particle can be consumed by an antigen presenting cell.
Three-group polymer-embedded single-species antigen particles with defined polymer selection and single-particle consumption sizing
A composition comprising a pharmaceutically acceptable carrier; first, second, and third groups of substantially spherical biocompatible-polymer particles each embedding a single antigen species consisting of eight to twenty amino acids, with the antigen species being different across the groups; wherein each particle has a diameter from 10 microns×120% to 25 microns×120% such that only a single particle can be consumed by an antigen presenting cell; and wherein the biocompatible polymer is selected from PLGA, polycaprolactone, polyglycolide, polylactic acid, or poly-3-hydroxybutyrate.
Multiple additional groups of polymer-embedded single-species antigens with single-particle consumption sizing
A composition comprising a pharmaceutically acceptable carrier; a first group and a second group of substantially spherical biocompatible-polymer particles, each embedding a single antigen species consisting only of eight to twenty amino acids and differing across the groups; and a plurality of additional groups of particles with a diameter such that only a single particle can be consumed by an antigen presenting cell, wherein additional antigens in each additional group are embedded in the polymer, are different from antigen in all other groups, and the antigens of each group consist only of a single species; wherein each particle has a diameter in a range from 10 microns×120% to 25 microns×120% and the biocompatible polymer is selected from PLGA, polycaprolactone, polyglycolide, polylactic acid, or poly-3-hydroxybutyrate.
Vaccine composition with three groups of polymer-embedded single-species antigens and narrowed particle diameter
A vaccine composition comprising a pharmaceutically acceptable carrier; a first group of substantially spherical biocompatible-polymer particles with a first antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer; a second group with a second antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the second antigen different from the first; and a third group with a third antigen consisting only of a single species consisting of eight to twenty amino acids embedded in the polymer, the third antigen different from both the first and second; wherein each particle has a diameter in a range from 10 microns×110% to 15 microns×110% such that only a single particle can be consumed by an antigen presenting cell.
Across the independent claims, the coverage centers on multi-group formulations containing polymer-embedded antigens where each group contains only one antigen species of eight to twenty amino acids, and the particles are substantially spherical and sized so that only a single particle can be consumed by an antigen presenting cell. The independent claims further specify particular polymer selections for some embodiments, and narrower diameter ranges for a vaccine composition embodiment.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?